Online citations, reference lists, and bibliographies.
← Back to Search

Which Type Of Surgery Should Become The Preferred Procedure For Malignant Pleural Mesothelioma: Extrapleural Pneumonectomy Or Extended Pleurectomy?

M. A. Bedirhan, L. Cansever, A. Demir, Süleyman Ceyhan, H. Akın, Halide Nur Urer, Aysun Olçmen, C. Kocatürk, I. Dinçer
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSES Since radiation and chemotherapy have limitations as therapies for malignant pleural mesothelioma (MPM). The type of surgery [extrapleural pneumonectomy (EPP), extended pleurectomy (E/P), and pleurectomy/decortication (P/D)] remains controversial. METHODS This study involves 76 consecutive patients. 58 of the cases were males (76%) with a median age of 53.17±10.93 years. EPP, E/P, and P/D were performed in 31, 20, and 25 cases, respectively. RESULTS The median survival time was 20 months in all patients. Overall, five-year survival rate was 14.3%. The survival rate was significantly better in epithelioid mesothelioma (P=0.049). For EPP cases, the median survival rate was 17 months, and the three-to-five year survival rates were 21% and 17%, respectively. For E/P cases, the median survival rate was 27 months and the three-year and four-year survival rates were 34% and 30%, respectively. For P/D cases, the median survival rate was 15 months and the three-to-five year survival rate was 13% and 0%. There were no statistically significant differences between the three surgical techniques (P=0.088). A comparative analysis indicates only a statistically significant difference in the E/P and P/D comparison (P=0.032). Hospital mortality showed a higher trend in EPP group (EPP: 12.9%, E/P: 0% and P/D: 4%, P=0.145). N2 cases, there were no cases of two-year survival. The survival rate in N2 was comparatively much lower, which was statistically significant (P=0.005). In multivariate analysis, only P/D (OR 0.3, 95% CI: 0.1-0.9, P=0.049) and N2 (OR 1.6, 95% CI: 0.9-2.6, P=0.090) were found to be poor prognostic factors. CONCLUSIONS E/P could be encouraged to EPP with lower mortality rate and better survival trend in MPM. N2 diseases were negative prognostic factors in MPM.
This paper references
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.3978/j.issn.2225-319X.2012.11.10
Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database.
V. Rusch (2012)
Neoadjuvant chemotherapy fol lowed by extrapleural pneumonectomy in malignant pleural mesothelioma
W Weder (2004)
10.1053/j.semtcvs.2009.06.008
Surgical options in malignant pleural mesothelioma: extrapleural pneumonectomy or pleurectomy/decortication.
R. Flores (2009)
10.1200/JCO.2004.10.071
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2004)
Which type of surgery should become the preferred procedure for malignant pleural mesothelioma: extrapleural pneumonectomy or extended pleurectomy?
M A Bedirhan (2013)
10.1016/j.ejcts.2009.04.044
Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies.
D. Trousse (2009)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1016/J.LUNGCAN.2005.03.015
Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience.
R. Flores (2005)
Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma.
V. Rusch (1997)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
10.4414/smw.2012.13686
Long term survival after trimodal therapy in malignant pleural mesothelioma.
R. Fahrner (2012)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1097/JTO.0b013e31824ab6c5
Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma
L. Lang-Lazdunski (2012)
10.1097/JTO.0b013e31815608d9
Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center
R. Flores (2007)
10.1097/JTO.0b013e31828353d7
Surgery in mesothelioma--where do we go after MARS?
B. Hiddinga (2013)
Case - control study between extrapleural pneumonectomy and radical pleurectomy / decortication for pathological N 2 malignant pleural mesothelioma
AE Martin-Ucar (2007)
10.3978/j.issn.2225-319X.2012.11.07
Systematic review of trimodality therapy for patients with malignant pleural mesothelioma.
C. Cao (2012)
10.1136/thorax.55.9.731
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
J. Edwards (2000)
10.1097/JTO.0b013e3181ae26ae
The Mesothelioma and Radical Surgery Randomized Controlled Trial: The MARS Feasibility Study
T. Treasure (2009)
WHO classification: pathology & genetics, tumours of the lung, pleura, thymus and heart
W D Travis (2004)
10.1186/1471-2407-13-22
Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma
R. Federico (2012)
10.1016/j.athoracsur.2009.01.026
Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma.
T. Yan (2009)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
[Gene therapy in malignant mesothelioma].
A. O. Tokat (2003)
10.1586/era.09.2
Future developments in the management of malignant pleural mesothelioma
Paolo Andrea Zucali (2009)
10.1093/icvts/ivs465
Multimodal therapy of malignant pleural mesothelioma: is the replacement of radical surgery imminent?
J. Lindenmann (2013)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1016/j.ejcts.2007.09.044
Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
P. Borasio (2008)
eds. WHO classification: pathology & genetics, tumours of the lung, pleura, thymus and heart
WD Travis (2004)
10.1016/J.ATHORACSUR.2004.01.034
The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma.
D. Stewart (2004)
10.1016/J.EJCTS.2007.01.064
Case-control study between extrapleural pneumonectomy and radical pleurectomy/decortication for pathological N2 malignant pleural mesothelioma.
A. Martin-Ucar (2007)
10.1136/thx.31.1.15
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)



This paper is referenced by
10.1016/j.jtcvs.2017.10.070
Diaphragm and lung–preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10‐year experience
M. Ambrogi (2018)
10.3390/jcm9072153
Should Lung-Sparing Surgery Be the Standard Procedure for Malignant Pleural Mesothelioma?
Y. Ichiki (2020)
10.1016/j.athoracsur.2014.09.056
Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma.
E. Taioli (2015)
10.2995/JACSURG.29.435
Evaluation of surgical treatment for malignant pleural mesothelioma
Hideyuki Nishi (2015)
10.1055/s-0034-1365025
[Malignant pleural mesothelioma: new aspects of medical therapy].
S. Kurz (2014)
10.18632/oncotarget.9964
Reduction of estradiol in human malignant pleural mesothelioma tissues may prevent tumour growth, as implied by in in-vivo and in-vitro models
B. Nuvoli (2016)
Surgical treatment for malignant pleural mesothelioma: extrapleural pneumonectomy, pleurectomy/decortication or extended pleurectomy?
P. Hountis (2015)
10.21037/atm.2017.03.88
A nuanced view of extrapleural pneumonectomy for malignant pleural mesothelioma.
I. Opitz (2017)
10.1016/j.lungcan.2013.11.026
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
10.1016/j.thorsurg.2016.04.003
Current Treatment of Mesothelioma: Extrapleural Pneumonectomy Versus Pleurectomy/Decortication.
A. Wolf (2016)
10.1002/jso.25260
Short‐term outcomes of pleurectomy decortication and extrapleural pneumonectomy in mesothelioma
M. V. van Gerwen (2018)
10.5606/TGKDC.DERGISI.2019.16162
A case of surgically treated bilateral metachronous malignant pleural mesothelioma.
M. A. Bedirhan (2019)
10.1007/978-3-030-16884-1_13
Surgery and Multimodality Treatment in Malignant Pleural Mesothelioma
F. Rea (2019)
10.1080/17476348.2017.1338951
Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma
G. Marulli (2017)
Semantic Scholar Logo Some data provided by SemanticScholar